<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03963297</url>
  </required_header>
  <id_info>
    <org_study_id>GMC-9</org_study_id>
    <nct_id>NCT03963297</nct_id>
  </id_info>
  <brief_title>Multicenter Evaluation of the Susceptibility of Enterobacteriaceae and Pseudomonas Aeruginosa to Ceftolozane/Tazobactam Combination</brief_title>
  <acronym>GMC-9</acronym>
  <official_title>Multicenter Evaluation of the Susceptibility of Enterobacteriaceae and Pseudomonas Aeruginosa to Ceftolozane/Tazobactam Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Paris Saint Joseph</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Paris Saint Joseph</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ceftolozane/tazobactam is a new antibiotic with broad spectrum activity. This molecule is
      currently one of the most active beta lactams against Pseudomonas aeruginosa and its spectrum
      of activity also includes enterobacteriaceae producing a broad spectrum beta-lactamase
      (EBLSE). Ceftolozane/tazobactam is currently marketed for the treatment of complicated
      intra-abdominal infections and complicated urinary tract infections. These intra-abdominal
      and urinary infections are mainly caused by enterobacteriaceae (Escherichia coli, Klebsiella
      pneumoniae) and more rarely by P. aeruginosa. Concerning enterobacteriaceae, French
      epidemiology reports a prevalence of BLSE of between 10 and 15% in E. coli and 10%-30% in K.
      pneumoniae.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, the probabilistic treatment of these multi-resistant bacteria involves the use of
      carbapenems. Unfortunately, the increasing and unreasonable use of carbapenems invariably
      leads to the spread of even more resistant strains, BHRe (Emerging Highly Resistant Bacteria)
      including enterobacteriaceae producing carbapenemases. Thus, it is strongly recommended by
      health authorities to limit the use of carbapenems (&quot;carbapenem savings&quot;) by promoting the
      use of therapeutic alternatives. Ceftolozane/tazobactam is one of those therapeutic
      alternatives for which an evaluation must be carried out. Currently, in addition to
      complicated intra-abdominal infections and complicated urinary tract infections,
      ceftolozane/tazobactam combination is used in clinical practice in gram-negative infections
      such as upper and lower respiratory infections and bacteremia. In any case, the choice of
      probabilistic antibiotic therapy must take into account local and regional epidemiological
      data. However, published data on the in vitro activity of ceftolozane/tazobactam remain
      limited, particularly in France (only one French epidemiological study on Gram-negative
      non-fermenting bacillus strains isolated in patients with cystic fibrosis). This study does
      not take into account in particular multi-resistant enterobacteriaceae producing BLSE for
      which ceftolozane/tazobactam remains effective (particularly in E. coli and K. pneumoniae).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Value of the minimum inhibitory concentration (MIC)</measure>
    <time_frame>1 year</time_frame>
    <description>Value of the minimum inhibitory concentration (MIC) obtained for ceftolozane/tazobactam for each strain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient History</measure>
    <time_frame>1 year</time_frame>
    <description>Clinical profil of patients (yes/no) correlated with resistance or susceptibility of strains to ceftolozane/tazobactam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of strains producing ESBL and/or carbapenemase (yes or no)</measure>
    <time_frame>1 year</time_frame>
    <description>biochemical tests (ESBL NDP test and/or Carba NP test)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular profil of enterobacteriaceae (produced genes : yes or no)</measure>
    <time_frame>1 year</time_frame>
    <description>Molecular test (PCR + sequencing: blaCTX-M, blaTEM, blaSHV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular profil of pseudomonas aeruginosa (produced genes : yes or no)</measure>
    <time_frame>1 year</time_frame>
    <description>Molecular test (PCR + sequencing : blaGES, blaVEB and blaPER)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Antibiotic Resistant Strain</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      For hospitalized patients who may have a community or nosocomial Gram-negative bacillus
      infection of the enterobacterial type or P. aeruginosa type, diagnostic specimens are taken
      by the clinical department and sent to the local microbiology laboratory for investigation,
      in accordance with standard management. Depending on the location, the samples may be AMLs
      (Bronchial-Alveolar Washing), PDPs (Protected Distal Sampling), blood culture, ascites,
      operating room samples or other puncture.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patient with community-acquired or nosocomial Gram-negative bacillus infection
        of enterobacteriaceae or P. aeruginosa type (bacteremia, low respiratory infection,
        intra-abdominal infection)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient whose age is ≥ 18 years old

          -  Hospitalized patient with community-acquired or nosocomial Gram-negative bacillus
             infection of enterobacteriaceae or P. aeruginosa type (bacteremia, low respiratory
             infection, intra-abdominal infection)

          -  French-speaking patient

        Exclusion Criteria:

          -  Patient under tutorship or curatorship

          -  Patient deprived of liberty

          -  Patient under the protection of justice

          -  Refusal to participate in the study

          -  Patients judged by the investigator as being unable to express their non-opposition to
             the study

          -  Urinary localization of the infection to avoid strains responsible for simple
             colonization. Indeed, the collection of microbiological data (as carried out in this
             study) makes it difficult to distinguish between real infection and simple
             colonization. In addition, the impact of early implementation of appropriate therapy
             on the evolution of infectious disease (mortality, morbidity, etc.) has been clearly
             demonstrated for serious infections such as bacteremia and respiratory infections,
             while this impact remains more limited or even insignificant for urinary infections.
             Hence the desire to exclude isolated strains of urine samples.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alban Le Monnier, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Paris Saint Joseph</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alban Le Monnier, Professor</last_name>
    <phone>01 44 12 79 32</phone>
    <phone_ext>+33</phone_ext>
    <email>alemonnier@hpsj.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BEAUSSIER Hélène, PhD, PharmD</last_name>
      <phone>+33 1 44 12 70 38</phone>
      <email>hbeaussier@hpsj.fr</email>
    </contact>
    <contact_backup>
      <last_name>CRC</last_name>
      <phone>+33 1 44 12 70 33</phone>
      <email>crc@hpsj.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015. Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02125-17. doi: 10.1128/AAC.02125-17. Print 2018 Mar.</citation>
    <PMID>29263073</PMID>
  </results_reference>
  <results_reference>
    <citation>Walkty A, Adam H, Baxter M, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16. J Antimicrob Chemother. 2018 Mar 1;73(3):703-708. doi: 10.1093/jac/dkx468.</citation>
    <PMID>29244121</PMID>
  </results_reference>
  <results_reference>
    <citation>Monogue ML, Nicolau DP. Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa. J Antimicrob Chemother. 2018 Apr 1;73(4):942-952. doi: 10.1093/jac/dkx483.</citation>
    <PMID>29272436</PMID>
  </results_reference>
  <results_reference>
    <citation>Munita JM, Aitken SL, Miller WR, Perez F, Rosa R, Shimose LA, Lichtenberger PN, Abbo LM, Jain R, Nigo M, Wanger A, Araos R, Tran TT, Adachi J, Rakita R, Shelburne S, Bonomo RA, Arias CA. Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa. Clin Infect Dis. 2017 Jul 1;65(1):158-161. doi: 10.1093/cid/cix014.</citation>
    <PMID>28329350</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen M, Zhang M, Huang P, Lin Q, Sun C, Zeng H, Deng Y. Novel β-lactam/β-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: a meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther. 2018 Feb;16(2):111-120. doi: 10.1080/14787210.2018.1429912. Epub 2018 Jan 24. Review.</citation>
    <PMID>29343141</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>May 22, 2019</last_update_submitted>
  <last_update_submitted_qc>May 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudomonas Infections</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

